Loading stock data…
Sarepta Therapeutics, Inc. (SRPT)
$20.94-1.56 (-6.93%)
Market ClosedLast close Sep 8
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sarepta Therapeutics, Inc. in the Healthcare sector is trading at $20.94 with a market capitalization of $2.2B. Wall Street consensus targets $22.26 (23 analysts), implying a +6.3% move over the next 12 months. The stock is currently 17% below its 52-week high of $25.32, remaining 9.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +6.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $730.80M↑ | $442.93M↑ | $399.36M↓ | $611.09M↓ | $744.86M |
| Gross Profit | $622.03M↑ | $44.23M↓ | $248.58M↓ | $458.53M↓ | $607.29M |
| Operating Income | $358.43M↑ | -$410.08M↓ | -$62.88M↓ | $115.58M↑ | -$300.39M |
| Net Income | $330.96M↑ | -$282.85M↓ | -$179.95M↓ | $196.89M↑ | -$447.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-8.95%
Volume
Today's trading volume
6.24M
Recent News
Novartis Stock Tanks Following Third Major Pipeline Setback
Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on...
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.